Skip to main content

Table 3 Frequency of AEs (N = 64)

From: Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

 

Any grade

Grade 3

Grade 4

TRAEs

 Any TRAEs

61 (95.3)

14 (21.9)

3 (4.7)

 Proteinuria

30 (46.9)

0 (0.0)

0 (0.0)

 Hypertension

23 (35.9)

2 (3.1)

0 (0.0)

 Hypothyroidism

20 (31.3)

0 (0.0)

0 (0.0)

 Aspartate aminotransferase increased

17 (26.6)

0 (0.0)

0 (0.0)

 Platelet count decreased

15 (23.4)

4 (6.3)

0 (0.0)

 Weight decreased

15 (23.4)

0 (0.0)

0 (0.0)

 Palmar-plantar erythrodysaesthesia syndrome

13 (20.3)

4 (6.3)

0 (0.0)

 Lipase increased

12 (18.8)

2 (3.1)

1 (1.6)

 Amylase increased

10 (15.6)

1 (1.6)

0 (0.0)

 Blood creatine phosphokinase MB increased

10 (15.6)

0 (0.0)

0 (0.0)

 Blood lactate dehydrogenase increased

10 (15.6)

0 (0.0)

0 (0.0)

 Blood bilirubin increased

9 (14.1)

0 (0.0)

0 (0.0)

 Rash

8 (12.5)

0 (0.0)

0 (0.0)

 White blood cell count decreased

7 (10.9)

1 (1.6)

0 (0.0)

 Haematuria

7 (10.9)

0 (0.0)

0 (0.0)

 Diarrhoea

7 (10.9)

0 (0.0)

0 (0.0)

 Dysphonia

7 (10.9)

0 (0.0)

0 (0.0)

imAEs

 Any imAEs

30 (46.9)

3 (4.7)

0 (0.0)

 Hypothyroidism

20 (31.3)

0 (0.0)

0 (0.0)

 Rash

8 (12.5)

0 (0.0)

0 (0.0)

 Hyperthyroidism

3 (4.7)

0 (0.0)

0 (0.0)

 Myositis

2 (3.1)

0 (0.0)

0 (0.0)

 Pancreatitis

2 (3.1)

2 (3.1)

0 (0.0)

 Thyroiditis

2 (3.1)

0 (0.0)

0 (0.0)

 Adrenal insufficiency

1 (1.6)

0 (0.0)

0 (0.0)

 Enterocolitis

1 (1.6)

1 (1.6)

0 (0.0)

  1. Data are presented as n (%). TRAEs at any grade occurring in ≥ 10% of patients are listed. No grade 5 adverse events occurred among TRAEs reported at an overall frequency of ≥ 10%. imAEs occurring in ≥ 1 patient. Data are listed in order of decreased frequency of any grade TRAE. AEs Adverse events, TRAEs Treatment-related adverse events, imAEs Immune-mediated adverse events